X0306 4 2022-01-06 false 0001689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN 0001373097 JONES WILLIAM A JR C/O BIOHAVEN PHARMACEUTICALS, INC. 215 CHURCH STREET NEW HAVEN CT 06510 false true false false CCO-Migraine & Common Disease Common Shares 2022-01-06 4 M false 5000.00 0.00 A 14110.00 D Common Shares 2022-01-06 4 F false 2230.00 123.86 D 11880.00 D Common Shares 2022-01-07 4 M false 3750.00 0.00 A 15630.00 D Common Shares 2022-01-07 4 F false 1631.00 128.87 D 13999.00 D Restricted Share Unit Award 2022-01-06 4 M false 5000.00 0.00 D Common Shares 5000.00 10000.00 D Employee Stock Option (right to buy) 128.87 2022-01-07 4 A false 30000.00 0.00 A 2032-01-07 Common Shares 30000.00 30000.00 D Restricted Share Unit Award 2022-01-07 4 A false 15000.00 0.00 A Common Shares 15000.00 15000.00 D Restricted Share Unit Award 2022-01-07 4 M false 3750.00 0.00 D Common Shares 3750.00 11250.00 D This balance includes 288 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2021. No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Each restricted share unit represents the contingent right to receive one common share of the Issuer. The reporting person was granted 20,000 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date. Not applicable. The shares underlying this option vest in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service with the Issuer at each vesting date. The reporting person was granted 15,000 restricted share units on January 7, 2022, vesting in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continued service with the Issuer at each vesting date. Exhibit List: Exhibit 24: Power of attorney /s/ George Clark, Attorney-in-Fact 2022-01-07